Citations

Clear

1446 citation(s) found for "Howard, F".

The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and Aβ amyloidosis
Choi, Jinkuk , Gao, Jie , Kim, Jaekwang , Kim, Jungsu , Tontonoz, Peter , Hong, Cynthia , Kim, Jungsu

Mayo Clinic

Science Translational Medicine | November 18, 2015 | Volume: 7 | Issue: 314 | Pages: No page available

10.1126/scitranslmed.aad1904 | PMID 26582899 Get It

Inhibiting the E3 ubiquitin ligase Idol in a mouse model of Alzheimer’s-like pathology ameliorates disease severity by promoting clearance of Aβ peptides by microglia.
Defining Rates and Risk Factors for Readmissions Following Emergency General Surgery
Havens, Joaquim M. , Olufajo, Olubode A. , Cooper, Zara , Haider, Adil H. , Shah, Adil A. , Salim, Alí , Cooper, Zara

Mayo Clinic

JAMA Surgery | November 11, 2015 | Volume: 151 | Issue: 4 | Pages: 330

10.1001/jamasurg.2015.4056 | PMID 26559368 Get It

Evaluation of the Perceived Association Between Resident Turnover and the Outcomes of Patients Who Undergo Emergency General Surgery
Shah, Adil A. , Zogg, Cheryl K. , Nitzschke, Stephanie , Changoor, Navin R. , Havens, Joaquim M. , Salim, Alí , Cooper, Zara , Haider, Adil H.

Mayo Clinic

JAMA Surgery | November 4, 2015 | Volume: 151 | Issue: 3 | Pages: 217

10.1001/jamasurg.2015.3940 | PMID 26536282 Get It

Pharmacogenomics of estrogens on changes in carotid artery intima-medial thickness and coronary arterial calcification: Kronos Early Estrogen Prevention Study
Miller, Virginia M. , Jenkins, Gregory D. , Heit, John A. , Huggins, Gordon S. , Hodis, Howard N., Budoff, Matthew J. , Løbo, Rogerio A. , Taylor, Hugh S. , Black, Dennis M. , Harman, S. Mitchell , de Andrade, Mariza, Biernacka, Joanna M. , Manson, JoAnn E. , Naftolin, Frederick , Andrade, Mariza de , Budoff, Matthew

Mayo Clinic

Physiological Genomics | October 28, 2015 | Volume: 48 | Issue: 1 | Pages: 33-41

10.1152/physiolgenomics.00029.2015 | PMID 26508701 Get It

Prior to the initiation of menopausal hormone treatment (MHT), genetic variations in the innate immunity pathway were found to be associated with carotid artery intima-medial thickness (CIMT) and coronary arterial calcification (CAC) in women ( n = 606) enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). Whether MHT might affect these associations is unknown. The association of treatment outcomes with variation in the same 764 candidate genes was evaluated in the same KEEPS participants 4 yr after randomization to either oral conjugated equine estrogens (0.45 mg/day), transdermal 17β-estradiol (50 μg/day), each with progesterone (200 mg/day) for 12 days each month, or placebo pills and patch. Twenty SNPs within the innate immunity pathway most related with CIMT after 4 yr were not among those associated with CIMT prior to MHT. In 403 women who completed the study in their assigned treatment group, single nucleotide polymorphisms (SNPs) within the innate immunity pathway were found to alter the treatment effect on 4 yr change in CIMT (i.e., significant interaction between treatment and genetic variation in the innate immunity pathway; P < 0.001). No SNPs by treatment effects were observed with changes of CAC >5 Agatston units after 4 yr. Results of this study suggest that hormonal status may interact with genetic variants to influence cardiovascular phenotypes, specifically, the pharmacogenomic effects within the innate immunity pathway for CIMT.
Interdomain B in ZAP-70 Regulates but Is Not Required for ZAP-70 Signaling Function in Lymphocytes
Zhao, Qihong , Williams, Brandi L., Abraham, Robert T. , Weiss, Arthur

Mayo Clinic

Molecular and Cellular Biology | October 26, 2015 | Volume: 19 | Issue: 1 | Pages: 948-956

10.1128/mcb.19.1.948 | PMID 9858619 Get It

Temporal Trends of Cardiac Chambers Function with Trastuzumab in Human Epidermal Growth Factor Receptor II–Positive Breast Cancer Patients
Moustafa, Sherif, Murphy, Katie , Nelluri, B.K., Northfelt, Donald W. , Shah, Parth , Lee, Howard , Wilansky, Susan , Naqvi, Tasneem Z. , Meyer, Susan M. , Mookadam, Farouk , Nelluri, Bhargava K, Northfelt, Donald, Meyer, Susan, Mookadam, Farouk

Mayo Clinic

Echocardiography | October 24, 2015 | Volume: 33 | Issue: 3 | Pages: 406-415

10.1111/echo.13087 | PMID 26498324 Get It

BackgroundTrastuzumab has substantially improved overall survival and reduced the risk of disease recurrence in patients with human epidermal growth factor receptor type II (HER‐II)–positive breast cancer. However, this benefit may be at the increased risk of cardiotoxicity. We aimed to explore the early subclinical left and right ventricular as well as atrial dysfunction, in trastuzumab‐treated patients with HER‐II–positive breast cancer, using velocity vector imaging.MethodsEchocardiography images were acquired in 50 patients with HER‐II–positive breast cancer undergoing trastuzumab therapy. All patients had baseline and 3–6 months and 12–15 months of follow‐up echocardiograms after initiation of trastuzumab therapy. Subendocardial borders of all the cardiac chambers were traced from the apical views to obtain volumetric and deformation indices.ResultsMean age was 60 ± 13 years. Left ventricular (LV) ejection fraction as well as conventional indices of right ventricular (RV) function did not change with trastuzumab. The RV peak systolic global longitudinal strain (GLε) significantly decreased (−24.53 ± 6.03 vs. −21.28 ± 5.11 vs. −21.84 ± 5.15, baseline vs. first and second follow‐ups, P = 0.01). LV peak systolic GLε was reduced by 1.19 at early follow‐up (P < 0.05). Left atrial reservoir and booster pump functions as well as right atrial reservoir function were reduced through follow‐up as well.ConclusionsThe RV exhibited greater change in strain after trastuzumab treatment when compared to the LV. Atria function was reduced by trastuzumab as well. The repercussion of these findings and their potential implication will warrant further study.
Time From Symptoms to Carotid Endarterectomy or Stenting and Perioperative Risk
Hopkins, L. Nelson , Altafullah, Irfan, Wechsler, Lawrence R. , Gonzales, Nicole R. , Voeks, Jenifer H. , Howard, George , Brott, Thomas G. , Stotts, Grant, Meschia, James F. , Stotts, Grant , Howard, George

Mayo Clinic

Stroke | October 23, 2015 | Volume: 46 | Issue: 12 | Pages: 3540-3542

10.1161/strokeaha.115.011123 | PMID 26493675 Get It

Background and Purpose— Prior meta-analysis showed that carotid endarterectomy benefits decline with increasing surgical delay following symptoms. For symptomatic patients in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST), we assessed if differences in time between symptoms and carotid endarterectomy or carotid artery stenting are associated with differences in risk of periprocedural stroke or death. Methods— We analyzed the 1180 symptomatic patients in CREST who received their assigned procedure and had clearly defined timing of symptoms. Patients were classified into 3 groups based on time from symptoms to procedure: <15, 15 to 60, and >60 days. Results— For carotid endarterectomy, risk of periprocedural stroke or death was not significantly different for the 2 later time periods relative to the earliest time period (hazard ratio, 0.74; 95% confidence interval, 0.22–2.49 for 15–60 days and hazard ratio, 0.91; 95% confidence interval, 0.25–3.33 for >60 days; P =0.89). For carotid artery stenting, risk of periprocedural stroke or death was also not significantly different for later time periods relative to the earliest time period (hazard ratio, 1.12; 95% confidence interval, 0.53–2.40 for 15–60 days and hazard ratio, 1.15; 95% confidence interval, 0.48–2.75 for >60 days; P =0.93). Conclusions— Time from symptoms to carotid endarterectomy or carotid artery stenting did not alter periprocedural safety, supporting early revascularization regardless of modality. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00004732.
Evidence for Direct Physical Association between a K+Channel (Kir6.2) and an ATP-Binding Cassette Protein (SUR1) Which Affects Cellular Distribution and Kinetic Behavior of an ATP-Sensitive K+ Channel
Alekseev, Alexey E., Krapivinsky, Grigory, Carrasco, Antonio J., Clapham, David E. , Lorenz, Eva , Carrasco, Antonio J., Terzic, André

Mayo Clinic

Molecular and Cellular Biology | October 10, 2015 | Volume: 18 | Issue: 3 | Pages: 1652-1659

10.1128/mcb.18.3.1652 | PMID 9488482 Get It

Abstract IA13: Acinar cell transdifferentiation sets the stage for early tumor heterogeneity
Takeuchi, Kenneth K., Halbrook, Christopher J. , DelGiorno, Kathleen E. , Crawford, Howard C.

Mayo Clinic

Cancer Research | October 5, 2015 | Volume: 75 | Issue: 13_Supplement | Pages: IA13-IA13

10.1158/1538-7445.panca2014-ia13 Get It

Abstract Prior to PanIN formation, acinar cells harboring oncogenic Kras gradually lose their acinar character and take on a ductal phenotype in a process known as acinar-to-ductal metaplasia. Rather than mimicking a normal pancreatic duct, metaplastic ducts take on a proliferative biliary progenitor phenotype, marked by the expression of SOX17 and PDX1 and the presence of numerous tuft cells, recently identified as a PanIN initiating cells. Manipulation of SOX17 and PDX1 in vivo reveal them to be a transdifferentiation promoter and suppressor, respectively, both greatly affecting tuft cell genesis and tumor formation. These opposing roles of developmental transcription factors during tumorigenesis implicate the usurpation of a differentiation program that significantly contributes to cellular heterogeneity within early pre-cancerous lesions of the pancreas. Citation Format: Kenneth K. Takeuchi, Kathleen E. Delgiorno, Christopher J. Halbrook, Howard C. Crawford. Acinar cell transdifferentiation sets the stage for early tumor heterogeneity. [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Innovations in Research and Treatment; May 18-21, 2014; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2015;75(13 Suppl):Abstract nr IA13.
Abstract A77: Investigating the role of ADAM10 in pancreatic tumor differentiation
Peverley, Louise V., Halbrook, Christopher J. , Hall, Jason C., Ardito-Abraham, Christine , Crawford, Howard C.

Mayo Clinic

Cancer Research | October 5, 2015 | Volume: 75 | Issue: 13_Supplement | Pages: A77-A77

10.1158/1538-7445.panca2014-a77 Get It

Abstract Pancreatic adenocarcinoma (PDAC) is the 4th most common cause of cancer related deaths in the United States and has a dismal 5-year survival rate of 6%. This prognosis is attributed the disease’s fast and asymptomatic progression to metastasis, leading to late diagnosis upon which time there are few treatment options available. The A Disintegrin and Metalloproteinase (ADAM) family are sheddase proteins known to regulate cell adhesion and function. This regulation can allow ADAMs to influence the ability of tumor cells to disseminate from the primary tumor and metastasize to distant organs. ADAM10, which is seen to be up-regulated in both chronic pancreatitis and PDAC, cleaves a variety of substrates including several cell adhesion molecules such as L1-CAM, N-Cadherin, and E-Cadherin. Using a conditional knockout for ADAM10 in the Kras+/G12D;Ptf1a+/Cre (KC) mouse model of pancreatic cancer, we have observed an absence of metastasis when ADAM10 is genetically ablated. To investigate the potential role that ADAM10 plays in this, we used a shRNA approach to knock-down ADAM10 expression in various human pancreatic cancer cells lines. Analysis of these cell lines suggests a partial restoration of a less aggressive, differentiated phenotype, consistent with the increased longevity of the ADAM10 knockout KC mice. Citation Format: Louise V. Peverley, Christopher J. Halbrook, Jason C. Hall, Christine M. Ardito, Howard C. Crawford. Investigating the role of ADAM10 in pancreatic tumor differentiation. [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Innovations in Research and Treatment; May 18-21, 2014; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2015;75(13 Suppl):Abstract nr A77.